November 1, 2012 — HIMSS opposes the Oct. 4 call from four House Republican leaders for the Department of Health and Human Services (HHS) to “immediately suspend the distribution of incentive payments until [the department] promulgates universal interoperable standards.”


Medtronic Inc. announced promising data from the Engager European Pivotal Trial for the investigational Medtronic Engager transcatheter aortic valve implantation (TAVI) system. The first results from the multi-center trial support the safety and clinical performance of the valve, which uses a transapical delivery approach to treat patients with severe aortic stenosis who were at high or extreme risk for surgical aortic valve replacement (SAVR).

November 1, 2012 — It looks as though drug-eluting balloons (DEBs), already widely used in Europe, are set to burst into the global market as heart conditions become a more common problem, states a new report by healthcare experts GBI Research.

November 1, 2012 — Terumo Interventional Systems announced the nationwide availability of its new Pinnacle Precision Access System, a new vascular access system specifically designed for smooth, efficient and reliable peripheral vascular access.


November 1, 2012 — InspireMD Inc. announced that its proprietary MGuard embolic protection stent (EPS) was shown to be significantly superior when compared to standard bare metal and drug-eluting stents in achieving complete ST resolution and restoring normal blood flow in a major study of 432 randomized patients undergoing emergency coronary intervention for potentially fatal heart attacks.



October 31, 2012 — Boston Scientific Corp. received CE mark approval for the Synergy everolimus-eluting platinum chromium (PtCr) coronary stent system featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.



Breast cancer patients who receive radiation treatment do not have a higher risk of long-term cardiac morbidity when compared to patients undergoing modified radical mastectomy (MRM), according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 54th Annual Meeting. This is the first study to document comprehensive, late cardiac outcomes 25 years after breast cancer treatment.


Subscribe Now